Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, conferences, and Skype calls has returned with a vengeance. What can you do, though? The world keeps spinning. To cope, we are firing up the coffee kettle and enjoying a hot cup of stimulation. Our choice today is, once again, peppermint mocha, for those tracking this obsession of ours. Meanwhile, here are some tidbits to get you going. Hope you have a smashing day and keep in touch…
As Purdue Pharma grapples with thousands of lawsuits blaming the company for contributing to the opioid crisis, the drug maker has signaled it may file bankruptcy. If that happens, some newly created subsidiaries are likely to come under scrutiny, STAT reports. Over the past year, Purdue launched two limited partnerships now marketing or developing drugs that were previously listed as part of the Purdue product portfolio. Several former Purdue execs run the companies, both of which are referred to as operating subsidiaries, and a Purdue entity holds trademark rights for their names.
About the Author Reprints
